Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W N Hait

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Cancer|April 1, 1993
Cyclosporine treatment of refractory T-cell lymphomasD L Cooper, I M Braverman, A H Sarris, et al.
American Journal of Clinical Oncology|June 1, 1994
Cisplatin, doxorubicin, mitomycin C, and 5-fluorouracil for the treatment of metastatic non-small cell lung cancer. Limited activity of an aggressive chemotherapy regimenJ R Murren, H J Durivage, A H Rosenberg, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Biochemical modulation of 5-fluorouracil with brequinar: results of a phase I studyA C Buzaid, G Pizzorno, J C Marsh, et al.
Oncology Research|January 1, 1993
A phase II trial of mitomycin C, 5-fluorouracil and radiation therapy in the treatment of unresectable non-small cell lung cancerJ R Murren, S Ganpule, R Papac, et al.
Molecular Pharmacology|June 1, 1990
Biochemical correlates of the antitumor and antimitochondrial properties of gossypol enantiomersC C Benz, M A Keniry, J M Ford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignanciesR S DiPaola, M M Rafi, V Vyas, et al.
The New England Journal of Medicine|September 17, 1998
Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancerR S DiPaola, H Zhang, G H Lambert, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 13, 1997
Identification of a new class of protein kinases represented by eukaryotic elongation factor-2 kinaseA G Ryazanov, M D Ward, C E Mendola, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Cancer|April 1, 1993
Cyclosporine treatment of refractory T-cell lymphomasD L Cooper, I M Braverman, A H Sarris, et al.
American Journal of Clinical Oncology|June 1, 1994
Cisplatin, doxorubicin, mitomycin C, and 5-fluorouracil for the treatment of metastatic non-small cell lung cancer. Limited activity of an aggressive chemotherapy regimenJ R Murren, H J Durivage, A H Rosenberg, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
Biochemical modulation of 5-fluorouracil with brequinar: results of a phase I studyA C Buzaid, G Pizzorno, J C Marsh, et al.
Oncology Research|January 1, 1993
A phase II trial of mitomycin C, 5-fluorouracil and radiation therapy in the treatment of unresectable non-small cell lung cancerJ R Murren, S Ganpule, R Papac, et al.
Molecular Pharmacology|June 1, 1990
Biochemical correlates of the antitumor and antimitochondrial properties of gossypol enantiomersC C Benz, M A Keniry, J M Ford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignanciesR S DiPaola, M M Rafi, V Vyas, et al.
The New England Journal of Medicine|September 17, 1998
Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancerR S DiPaola, H Zhang, G H Lambert, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 13, 1997
Identification of a new class of protein kinases represented by eukaryotic elongation factor-2 kinaseA G Ryazanov, M D Ward, C E Mendola, et al.
Pageof 7